Medical Health & Life Science Research News

New report shares details about the tyrosine protein kinase mer

Medical Market Research

'Tyrosine Protein Kinase Mer - Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase Mer targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells.

It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis.

It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

Complete Report Available at www.themarketreports.com/report/ty…ne-review-h2-2017  

Scope

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics

Access this Report at www.themarketreports.com/report/941688  

Companies Mentioned

  • Basilea Pharmaceutica Ltd
  • Celldex Therapeutics Inc
  • Celon Pharma SA
  • Dong-A Socio Holdings Co Ltd
  • Elsalys Biotech SAS
  • Ignyta Inc
  • Ono Pharmaceutical Co Ltd
  • Qurient Co Ltd
  • Rigel Pharmaceuticals Inc
  • SignalChem Lifesciences Corp

Inquire About this Report at www.themarketreports.com/report/ask-your-query/941688

News From

The Market Reports - Industry & Market Reports at its BESTThe Market Reports
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
This email address is being protected from spambots. You need JavaScript enabled to view it.